Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. - Wikidata - awgldk - TriplyDB

Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.

Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.

http://www.wikidata.org/entity/Q36937117

about

Exploiting tumor epigenetics to improve oncolytic virotherapy Oncolytic viruses as therapeutic cancer vaccines Systemic delivery of oncolytic viruses: hopes and hurdles Thunder and lightning: immunotherapy and oncolytic viruses collide Intelligent design: combination therapy with oncolytic viruses Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade From scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancer Oncolytic virotherapy for human malignant mesothelioma: recent advances Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers.Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production.Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors.Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates Impact of tumor microenvironment on oncolytic viral therapy Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?Vesicular stomatitis virus infection promotes immune evasion by preventing NKG2D-ligand surface expression Histone deacetylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cells Myxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity.Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent.Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1 Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma.Activation of Cyclic Adenosine Monophosphate Pathway Increases the Sensitivity of Cancer Cells to the Oncolytic Virus M1 HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy.Murine Tumor Models for Oncolytic Rhabdo-Virotherapy.CD8(+) T-cell Immune Evasion Enables Oncolytic Virus Immunotherapy Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics.Oncolytic myxoma virus: the path to clinic Interferon alpha bioactivity critically depends on Scavenger receptor class B type I function.Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis.Pharmacologic and chemical adjuvants in tumor virotherapy.The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon.Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways.In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer models Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-κB-dependent autophagy Bugs and drugs: oncolytic virotherapy in combination with chemotherapy.Entinostat for treatment of solid tumors and hematologic malignancies.Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses.Oncolytic virotherapy Oncolytic vaccines.

P2860

Q21131237-39861BD5-E2F3-4516-9484-DA0A92B0AD95 Q21245758-557185CC-B0B9-4819-BEBD-02348B82C322 Q21284969-D8071E8E-9EA2-4DE9-9AFF-739D4CDC84C7 Q24597894-16278AE7-0187-419B-9B99-8F0CD325EDE0 Q24628227-409E80BB-7CB9-480D-A6BF-C2E3DB824D9B Q26769977-4C14686D-CC04-4688-8E3F-37CC9894618B Q26822694-9FB008A6-765C-4121-B865-3537D5310360 Q26826590-62F55289-4598-4145-9A5C-8BD8D521C174 Q27021839-B887BCBD-F0D3-4276-952B-26BD1D90AA69 Q33554262-41ED1905-A8D2-44CA-A05B-9E8399E2D3AF Q33667768-511C3250-3EFF-4220-99C1-4D51B4A0E7FB Q33691838-96861286-B64F-4486-86F5-2007691112AA Q33808504-1C2027EA-C484-4A0D-B08F-9F36B3A264A6 Q33832168-85E04070-B249-4A95-8ACF-F1B5F213CA0B Q33895533-A2865D47-94D3-4B83-BA6C-0C24428F3F75 Q33995471-94B3BEDE-4934-40D1-96BA-D6A3726D408E Q33999130-9CA50E40-D21F-4347-9CC9-FCD334978D10 Q35126723-95967258-5772-40A1-8336-5BA4D6069E11 Q35216344-FA94C1D8-0C03-43FB-8F4E-935F8D8568A9 Q35275179-B30262F0-DF77-4DFF-893A-C21D36D70D62 Q36202610-2AB80779-0311-4018-85A8-403F4DB39781 Q36266545-730D5064-DAD5-4A0E-B863-915163DAE2C6 Q36582828-258D1426-F59C-4AD7-9A05-84ED7165D6AD Q36740297-4350739E-9018-490C-AEB3-484631B67BFF Q36751597-50ABD808-6BDC-458D-B018-C68524F33ACE Q36753953-38CC0CF2-0C5E-4D53-8A83-D9FB7CE762D0 Q36793937-B19E4DFA-AE2A-4247-8635-DDFC59B2BF54 Q37126088-B084C800-37CD-4F39-B5AD-0A063CF8E3B4 Q37224572-993664E4-A43A-446C-935B-794B939713B7 Q37316872-1A69352B-F002-4C6D-B366-7B7DFB7C8C78 Q37492540-61624432-0174-4D32-B95B-C46FCF06DFBD Q37561072-0F8FEF0A-64B2-42C5-8888-87613F6D0FFE Q37564490-90136873-5125-47FC-BFF4-BC3A6CEED9A7 Q37629550-D4C4C6B7-0DC3-4BFD-9D22-61AECEE320BA Q37644099-FBA56A34-8F53-40FA-BF1A-B122157014BD Q37899223-1C9A68A6-9F26-4B11-83AB-993618B459EB Q37925846-54D75673-3A7C-44A5-928C-9FA0591B7903 Q37933439-4925DDDF-AC84-44C1-8870-16CEF3F9D95B Q38025263-947CBB1E-A47E-4A8D-8B16-BA86162CEC4D Q38152474-4BE12BAF-8D7E-4324-9219-4433C6B85B84

P2860

Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.

http://www.wikidata.org/entity/Q36937117

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Chemical targeting of the inna ...... sensitive to viral oncolysis.

@en

type

label

Chemical targeting of the inna ...... sensitive to viral oncolysis.

@en

prefLabel

Chemical targeting of the inna ...... sensitive to viral oncolysis.

@en

P1433

Q36937117-BEB14EE2-23A0-4F38-96A3-A0E05DCEF50E

P1476

Q36937117-7DBD8605-CC73-49BC-9D13-AEC7827DDBD9

P2093

Q36937117-0FE91D7E-D397-4D69-A994-BCDB6E354CC4

Q36937117-31989203-DE02-4D12-8ADD-588EFF65FF53

Q36937117-403DE054-4701-46CB-8A9A-253021D66F8E

Q36937117-43888CEC-8309-4317-AA20-B31FECD45223

Q36937117-443B5701-2B76-428A-BB33-963368361697

Q36937117-51F62E4F-B171-4E0D-8344-A41DCEC9FED5

Q36937117-56CE8BA2-0F31-4B30-9361-D780A3DB2110

Q36937117-5D702638-D195-468E-9523-3CA14AD602F1

Q36937117-6E14A6C9-8CED-41EF-97DF-9D1407EC5841

Q36937117-731D4F5F-0D63-4972-A731-690BBB1920B3

P2860

Q36937117-08969A70-6260-4658-B416-EEDDF224C797

Q36937117-08BC3819-2438-4773-89B0-33E7F5DF22C0

Q36937117-13572F2B-F54E-4A7B-A818-91EDD176AC51

Q36937117-1458319D-F9C0-4BE2-BD1E-4F001485EEB4

Q36937117-14910568-A7EA-42A0-BA17-23FD844648D0

Q36937117-1AB75A36-2251-469F-94EB-508A5F5625DC

Q36937117-1CCEFBED-B676-4B45-98C1-52D629BAEBAB

Q36937117-1E89711D-4E51-406B-AB3C-03A0311AD7B7

Q36937117-1FA836AF-1AC9-49A7-B379-38F891C936EE

Q36937117-22153EF4-5899-4E2F-A4B5-51108B86C1F0

P304

Q36937117-8DAEB10C-0D22-488E-AFBA-C2D4AAF0AE13

P31

Q36937117-E02D3038-0286-44E6-B362-33DE98831094

P356

Q36937117-0D042521-5DA1-490E-83E9-2BF2783FE7C4

P407

Q36937117-138BF1B8-8265-4DF6-B07C-3A4DA458B33F

P433

Q36937117-189AE397-DE2E-490F-9BA6-C7380D7DFDB7

P478

Q36937117-54ADCABA-F8D8-4893-90CD-ED8FABA10AD4

P50

Q36937117-71878DBF-2E5C-49C8-AB77-5D4750D808B8

Q36937117-FB0969DB-B467-4F6A-A360-B4F3DC8F639F

P577

Q36937117-70988FCF-265A-4802-8B8E-3A0E419B7B28

P5875

Q36937117-DF1900DA-3D36-485C-BF18-8DCBEBCEC0F1

P698

Q36937117-9E5D6C00-124F-4FA8-B895-1F170C7702A6

P932

Q36937117-EEEE7A42-1B47-4C50-A2E3-7422670DC2AD

P356

PNAS.0803988105

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Chemical targeting of the inna ...... s sensitive to viral oncolysis

@en

P2093

Amber Yasmeen

http://www.w3.org/2001/XMLSchema#string

Barbara C Vanderhyden

http://www.w3.org/2001/XMLSchema#string

Caroline Breitbach

http://www.w3.org/2001/XMLSchema#string

David F Stojdl

http://www.w3.org/2001/XMLSchema#string

David Kirn

http://www.w3.org/2001/XMLSchema#string

Harold Atkins

http://www.w3.org/2001/XMLSchema#string

Hesham Abdelbary

http://www.w3.org/2001/XMLSchema#string

Jean-Simon Diallo

http://www.w3.org/2001/XMLSchema#string

Joel Werier

http://www.w3.org/2001/XMLSchema#string

John Hiscott

http://www.w3.org/2001/XMLSchema#string

P2860

Positive and negative regulation of the innate antiviral response and beta interferon gene expression by deacetylation.

Activation of TBK1 and IKKvarepsilon kinases by vesicular stomatitis virus infection and the role of viral ribonucleoprotein in the development of interferon antiviral immunity

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Interferons, immunity and cancer immunoediting

Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug

Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.

Alpha/beta interferons potentiate virus-induced apoptosis through activation of the FADD/Caspase-8 death signaling pathway

P304

14981-14986

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0803988105

http://www.w3.org/2001/XMLSchema#string

P407

P433

39

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-09-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23280712

http://www.w3.org/2001/XMLSchema#string

P698

18815361

http://www.w3.org/2001/XMLSchema#string

P932

2567479

http://www.w3.org/2001/XMLSchema#string